SCHEMBL30470933

SCHEMBL30470933

Cc1ccc(-c2ccc(C)c(C)c2)nc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCR1 P32246 1/20 0.58
CCR5 P51681 1/20 0.58
CCR8 P51685 1/20 0.58
HDAC6 Q9UBN7 1/20 0.58
CYP3A4 P08684 1/20 0.50
CYP2A6 P11509 1/20 0.50
NPC1 O15118 1/20 0.50
METAP2 P50579 1/20 0.43
GRIA2 P42262 1/20 0.43
USP2 O75604 1/20 0.42
MAPT P10636 1/20 0.42
P2RX7 Q99572 1/20 0.41
KDM1A O60341 3/20 0.41
PTGS2 P35354 2/20 0.41
ALPL P05186 1/20 0.40
CA9 Q16790 1/20 0.40
NOS3 P29474 1/20 0.39
NOS2 P35228 1/20 0.39
GRM5 P41594 1/20 0.39
HSD17B1 P14061 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16542435 1.00 CCR1 (0.58) CCR1CCR5CCR8HDAC6CYP3A4
SCHEMBL14569988 0.83 CCR1 (0.52) CCR1CCR5CCR8HDAC6CYP3A4
SCHEMBL19713104 0.83 CCR1 (0.52) CCR1CCR5CCR8HDAC6CYP3A4
SCHEMBL16385299 0.83 HSD17B1 (0.55) CCR1CCR5CCR8HDAC6CYP3A4
SCHEMBL3342956 0.83 CYP11B1 (0.52) CCR1CCR5CCR8HDAC6CYP3A4
SCHEMBL30751969 0.83 CCR1 (0.52) CCR1CCR5CCR8HDAC6CYP3A4
SCHEMBL17051514 0.83 CCR1 (0.75) CCR1CCR5CCR8HDAC6CYP3A4
SCHEMBL12128014 0.82 CCR1 (0.60) CCR1CCR5CCR8HDAC6CYP3A4
SCHEMBL13483666 0.81 CCR1 (0.71) CCR1CCR5CCR8HDAC6CYP3A4
SCHEMBL2477927 0.81 CCR1 (0.71) CCR1CCR5CCR8HDAC6CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4188920-A1 PIPERIDIN-1-YL-N-PYRYDINE-3-YL-2-OXOACETAMIDE DERIVATIVES USEFUL FOR THE TREATMENT OF MTAP-DEFICIENT AND/OR MTA-ACCUMULATING CANCERS Tango Therapeutics, Inc. (US) 2023-06-07 EP disclosed